Where I see patients (1)
Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways.
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.
Frontiers in oncology
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With G...
Will be calculated as the number of days from the date of patient registration to the date of death.
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Overall survival is defined from the time of randomization to death from any cause. Patients still alive at the time of an analysis will be considered censored at their date of last contact.
Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2 in Subjects With Progres...
Safety and tolerability of SONALA-001 SDT Definitions of Dose Limiting Toxicities (DLTs): The DLT window is the 21-day period following the first study treatment per patient. DLTs are defined as the following events during the DLT...
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
MTD is defined as the maximal dose at which fewer than one-third of participants experience a dose-limiting toxicity (DLT).
AB154 Combined With AB122 for Recurrent Glioblastoma
Adverse events will be listed individually by patient and treatment group. The number of patients experiencing each adverse event will be summarized by organ and grade. The number and percentage of patients with adverse events in ...
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patien...
The BAI is a 21-item self-report measure used to rate subjective, somatic, and panic-related symptoms of anxiety on a scale of 0 to 3 (higher scores indicating more anxiety).
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Pati...
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
To compare overall survival (OS) in patients with newly diagnosed glioblastoma between treatment arms A & B
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Number of Participants with a Dose-Limiting Toxicity (DLT)